Aptamer–drug conjugate: targeted delivery of doxorubicin in a HER3 aptamer-functionalized liposomal delivery system reduces cardiotoxicity

INTRODUCTION: The toxic side effects of doxorubicin (DOX) have limited its use in chemotherapy. Neither liposomal DOX nor pegylated liposomal DOX are able to completely resolve this issue. This is a proof-of-concept study testing aptamer-drug conjugate (ApDC) targeted delivery systems for chemothera...

Descripción completa

Detalles Bibliográficos
Autores principales: Dou, Xiao-qian, Wang, Hua, Zhang, Jing, Wang, Fang, Xu, Gui-li, Xu, Cheng-cheng, Xu, Huan-hua, Xiang, Shen-si, Fu, Jie, Song, Hai-feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5804143/
https://www.ncbi.nlm.nih.gov/pubmed/29440899
http://dx.doi.org/10.2147/IJN.S149887

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5804143/
https://www.ncbi.nlm.nih.gov/pubmed/29440899
http://dx.doi.org/10.2147/IJN.S149887

Ejemplares similares